GUMDROP : CUA - A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease

Created by Nancy Dawson, last modified on Jun 01, 2013
Description:The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown.
Link:http://clinicaltrials.gov/ct2/show/NCT01314118
Site:Chesapeake Urology Associates
Principal Investigator:Janssen Services, LLC. Clinical Trial